Article
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
21 Mar 2006
Abstract excerpt
Around 20% to 30% of patients with Hodgkin lymphoma (HL) do not benefit from standard therapies and finally succumb to their disease. The factors that influence the outcome of HL have not been elucidated, underscoring the demand for the identification of biologic risk factors and new therapeutic targets. We analyzed the gene expression profiles of samples from 29 patients with advanced classic HL treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
